Tel: +44(0)20 7691 0984 Email: Newsletter Sign Up
  • CEO Mark Duxon interviewed by The Pharma Letter on impact of Brexit on CROs...
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • State-of-the-art premises opening this month at Discovery Park in Kent...
  • Newly published work in Frontiers in Psychiatry demonstrating
  • the effectiveness of a clinically relevant dose of ketamine...
  • Head to 2021 conferences page to see titles of abstracts...


Mismatch-negativity (MMN) is regarded as one of the most highly translatable studies around. It has proven invaluable in the field for developing drugs for schizophrenia.

What is MMN?

Mismatch negativity (MMN) is a negative component of the event-related response in an EEG signal, elicited by any perceptible change in some repetitive aspect of an auditory stimulation.

What we do?

We've applied our expertise in EEG to develop rodent mismatch negativity (MMN). We can conduct strict clinical research studies under specified conditions and provide you with reliable, quality data.

Contact us today to discuss your project requirements and get things underway: Tel: +44 (0)20 7691 0984 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Start a Conversation

uk flag+44 (0)20 7691 0984

ireland flag+353 (0)1896 42 60

poland flag+48 515 244 120



Copyright © 2021 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design